Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NALIRIFOX Versus mGAP in Locally Advanced and Metastatic Pancreatic Adenocarcinoma
NCT07076212Phase 2Recruiting
- Sponsor
- Medical University of South Carolina
- Start
- Apr 2026
- Primary completion
- May 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, paclitaxel, cisplatin in pancreatic ductal adenocarcinoma (PDAC), sponsored by Medical University of South Carolina. Started Apr 2026; status: recruiting.
02
Drugs
gemcitabinepaclitaxelcisplatin
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07076212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07076212.